[144] Thermo Fisher Scientific, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filing for Thermo Fisher Scientific, Inc. (TMO) shows an intended sale of 400 shares of common stock through Fidelity Brokerage Services on 09/05/2025, with an aggregate market value listed as $200,201 and the transaction to occur on the NYSE. The 400 shares were acquired by option grant on 02/26/2019 and payment is indicated as cash on 09/05/2025. The filing also discloses recent sales by Marc N. Casper totaling 28,496 shares across five transactions in August 2025, producing gross proceeds of approximately $13.41 million. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Positive

• Transparent compliance with Rule 144: the filing specifies broker, share counts, acquisition dates, and sale dates
• Detailed prior sales disclosure: five August 2025 transactions are itemized with dates and gross proceeds, aiding investor transparency

Negative

• Insider selling by Marc N. Casper totaling approximately $13.41 million in August 2025 may be viewed negatively by some investors
• Planned sale of 400 shares on 09/05/2025 indicates continued insider disposition of shares

Insights

Securities Analyst

TL;DR Insider sales disclosed: small planned sale and significant August dispositions totaling about $13.4M, indicating liquidity-taking rather than new information.

The filing documents a scheduled sale of 400 shares (market value $200,201) by means of an option exercised from a 2019 grant, to be executed through Fidelity on 09/05/2025. Separately, Marc N. Casper reported five sales in August 2025 totaling 28,496 shares for roughly $13.41 million in gross proceeds. Relative to the issuer’s reported outstanding shares of 377,612,121, these transactions are immaterial to share count but represent meaningful cash realized by the insider. The filing is routine disclosure under Rule 144 and provides transparency on insider liquidity without revealing nonpublic operational details.

Corporate Governance Expert

TL;DR Transactions are lawful Rule 144 disclosures; pattern shows periodic insider selling but no stated connection to undisclosed adverse information.

The notice includes the required representation that the seller is unaware of any undisclosed material adverse information and lists the provenance of the 400 shares as an option grant from 02/26/2019. The August sales by Marc N. Casper are fully itemized with dates, amounts, and gross proceeds. From a governance perspective, the filing meets disclosure obligations and supports market transparency. There is no information in the form indicating any policy breaches or insider-trading issues, but the volume of prior August sales may prompt investor attention to executive share dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	400	200201.00	377612121	09/05/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Option Granted - 02/26/2019	Issuer			400	09/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/06/2025	10000	4518207.00
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/07/2025	8000	3635549.60
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/19/2025	201	100533.57
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/20/2025	295	147512.36
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/22/2025	10000	5009588.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 for Thermo Fisher (TMO) report?

The form reports a proposed sale of 400 common shares through Fidelity on 09/05/2025 with an aggregate market value of $200,201 and lists prior August 2025 sales by Marc N. Casper totaling 28,496 shares for about $13.41 million.

Who sold shares according to the filing?

The filing identifies Marc N. Casper as the seller in multiple August 2025 transactions and the person for whose account the 400-share sale is proposed.

How were the 400 shares acquired?

The 400 shares were acquired by an option granted on 02/26/2019, and payment for the proposed sale is listed as cash on 09/05/2025.

Through which broker will the proposed sale occur?

The proposed sale of 400 shares lists Fidelity Brokerage Services LLC as the broker (address provided in the filing) and the sale is to occur on the NYSE.

Are there any representations about undisclosed information in the filing?

Yes, the signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.